Jill A. Howe - 09 Mar 2023 Form 4 Insider Report for Lineage Cell Therapeutics, Inc. (LCTX)

Role
Chief Financial Officer
Signature
/s/ Grant Harbert, as Attorney-in-Fact
Issuer symbol
LCTX
Transactions as of
09 Mar 2023
Transactions value $
$0
Form type
4
Filing time
10 Mar 2023, 18:02:18 UTC
Previous filing
05 Jan 2023
Next filing
16 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LCTX Employee Stock Option (Right to Buy) Award $0 +150K $0.00 150K 09 Mar 2023 Common Shares 150K $1.46 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One quarter of the options shall vest on March 9, 2024, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.